المؤلفون: Arnaud Guille, Jihane Pakradouni, Max Chaffanet, Séverine Garnier, Christelle Levy, Marie Robert, Jean Marie Boher, Anthony Gonçalves, Cecile Vicier, Cornel Popovici, José Adélaïde, Daniel Birnbaum, Florence Dalenc, Patrick Sfumato, Nadine Carbuccia, Renaud Sabatier, Keyvan Rezai, Nicolas Isambert, Emmanuelle Charafe-Jauffret, François Bertucci, Magali Provansal

المساهمون: Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Sabatier, Renaud, Dupuis, Christine, Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Institut Claudius Regaud, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), CRLCC René Gauducheau, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Curie - Saint Cloud (ICSC), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: European Journal of Cancer
European Journal of Cancer, 2021, 159, pp.205-214. ⟨10.1016/j.ejca.2021.09.040⟩

مصطلحات موضوعية: Adult, Oncology, Cancer Research, medicine.medical_specialty, Paclitaxel, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Population, Triple Negative Breast Neoplasms, P70-S6 Kinase 1, [SDV.CAN]Life Sciences [q-bio]/Cancer, PI3K, chemistry.chemical_compound, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Enzyme Inhibitors, Adverse effect, education, ComputingMilieux_MISCELLANEOUS, Aged, Chemotherapy, education.field_of_study, business.industry, AKT, Ribosomal Protein S6 Kinases, 70-kDa, Cancer, Middle Aged, Metastatic breast cancer, medicine.disease, [SDV] Life Sciences [q-bio], chemistry, Toxicity, Female, business, Proto-Oncogene Proteins c-akt

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8522dd2e4d78727ec43433cf5ba566fTest
https://hal.science/hal-03622797Test

المؤلفون: Didier Blaise, Tycel Phillips, Jason T. Romancik, Roch Houot, Robert Lowsky, Martina Sollini, Jean Marc Schiano De Colella, Amer Beitinjaneh, Gunjan L. Shah, Lazaros J. Lekakis, Stephen D. Smith, Paolo Corradini, Mohamad Mohty, Maryam Rahimian, Luca Castagna, Taiga Nishihori, Asad Bashey, Talha Badar, Reid W. Merryman, Mehdi Hamadani, Carmelo Carlo-Stella, Dipenkumar Modi, Sally Arai, Kamal Bouabdallah, Valter Torri, Joseph P. McGuirk, Guillaume Manson, Anna Guidetti, Yi-Bin Chen, Hatcher J. Ballard, Julio C. Chavez, Pier Luigi Zinzani, Tatyana Feldman, Sunita Nathan, Anurag K. Singh, Massimo Magagnoli, Marie Pierre Moles-Moreau, Beatrice Casadei, Anthony Serritella, Michael Byrne, Radhakrishnan Ramchandren, Miguel-Angel Perales, Chiara De Philippis, Samantha Jaglowski, Justin Kline, Remy Dulery, Laura Giordano, Alex F. Herrera, Jonathon B. Cohen, Philippe Armand, Armando Santoro, Aspasia Stamatoulas, Stephen M. Ansell, Michael A. Spinner, Lori Dahncke, Corentin Orvain, Chloé Spilleboudt, Geoffrey Shouse, Robin Joyce, Vincent T. Ho, Matthew J. Frigault, Ryan C. Lynch, Uttam Rao, Jakub Svoboda, David A. Bond, Yago Nieto

المساهمون: Dana-Farber Cancer Institute [Boston], Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Università degli Studi di Milano = University of Milan (UNIMI), University of Bologna/Università di Bologna, Ohio State University [Columbus] (OSU), Stanford University, Memorial Sloane Kettering Cancer Center [New York], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux [Bordeaux], Humanitas University [Milan] (Hunimed), P01 CA23766, U.S. Department of Health & Human Services | National Institutes of Health, U.S. Department of Health & Human Services | National Institutes of Health, 20575, Associazione Italiana per la Ricerca sul Cancro, Università degli Studi di Milano [Milano] (UNIMI), University of Bologna, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Merryman R.W., Castagna L., Giordano L., Ho V.T., Corradini P., Guidetti A., Casadei B., Bond D.A., Jaglowski S., Spinner M.A., Arai S., Lowsky R., Shah G.L., Perales M.-A., De Colella J.M.S., Blaise D., Herrera A.F., Shouse G., Spilleboudt C., Ansell S.M., Nieto Y., Badar T., Hamadani M., Feldman T.A., Dahncke L., Singh A.K., McGuirk J.P., Nishihori T., Chavez J., Serritella A.V., Kline J., Mohty M., Dulery R., Stamatoulas A., Houot R., Manson G., Moles-Moreau M.-P., Orvain C., Bouabdallah K., Modi D., Ramchandren R., Lekakis L., Beitinjaneh A., Frigault M.J., Chen Y.-B., Lynch R.C., Smith S.D., Rao U., Byrne M., Romancik J.T., Cohen J.B., Nathan S., Phillips T., Joyce R.M., Rahimian M., Bashey A., Ballard H.J., Svoboda J., Torri V., Sollini M., De Philippis C., Magagnoli M., Santoro A., Armand P., Zinzani P.L., Carlo-Stella C.

المصدر: Leukemia
Leukemia, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (9), pp.2672-2683. ⟨10.1038/s41375-021-01193-6⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, allogenic stem cell transplantation, PD-1 blockade, Hodgkin lymhpoma, [SDV]Life Sciences [q-bio], Programmed Cell Death 1 Receptor, Salvage therapy, 0302 clinical medicine, Young adult, Immune Checkpoint Inhibitors, ComputingMilieux_MISCELLANEOUS, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Prognosis, Hodgkin Disease, 3. Good health, Survival Rate, surgical procedures, operative, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Allogeneic transplantation, Cyclophosphamide, Adolescent, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Transplantation, Homologous, Survival rate, Aged, Retrospective Studies, Salvage Therapy, business.industry, Retrospective cohort study, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Blockade, Transplantation, 030104 developmental biology, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local, business, Follow-Up Studies

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35becb5c5a55058afd6585d16fefe3a8Test
https://univ-rennes.hal.science/hal-03229516Test

المؤلفون: Clémentine Carlet, Marie Blanche Valnet-Rabier, Julie Castagna, Charlée Nardin, Kevin Bouiller, Flora Dresco, Virginie Nerich, François Aubin, Eve Puzenat, Samuel Limat, Adrien Mareschal, Anne Jeand'heur

المساهمون: Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département d'allergie et d'immunologie clinique [CHU Lyon Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Pôle pharmaceutique [CHRU Besançon], Département de pharmacie, Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

المصدر: Journal of The American Academy of Dermatology
Journal of The American Academy of Dermatology, Elsevier, 2020, 82 (3), pp.770-772. ⟨10.1016/j.jaad.2019.11.017⟩

مصطلحات موضوعية: Adult, Male, Skin Neoplasms, Programmed Cell Death 1 Receptor, Vitiligo, Dermatology, Antibodies, Monoclonal, Humanized, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Programmed cell death 1, medicine, Humans, Melanoma, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Aged, 80 and over, biology, business.industry, Middle Aged, medicine.disease, 3. Good health, Survival Rate, Nivolumab, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Female, Drug Eruptions, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d054e20ec5d489e7775983a14ec4ae33Test
https://hal.archives-ouvertes.fr/hal-02559044Test

المؤلفون: Sylvie Cénée, Anne Boland, Florence Menegaux, Brigitte Trétarre, Pierre Laurent-Puig, Robert Olaso, Xavier Rebillard, Claire Mulot, Hélène Blanché, Pierre-Jean Lamy, Jean-François Deleuze, Thérèse Truong, Geraldine Cancel-Tassin, Olivier Cussenot, Méyomo G. Wendeu-Foyet, Yves Akoli Koudou

المساهمون: Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Registre des tumeurs de l'Hérault, CRISAP-LR, COLRIM, EPC du CRLC-Centres privés de radiothérapie de l'Hérault-Laboratoires d'Hématologie CPAM - MSA - Caisse militaire, Clinique Beau Soleil [Montpellier], Centre de Recherche pour les Pathologies Prostatiques [Paris] (CeRePP), Sorbonne Université (SU), Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Département de santé publique, Centre National de Recherche en Génomique Humaine [Évry] (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Centre d'Etude du Polymorphisme Humain (CEPH), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset-Université de Paris (UP), Labosud, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail, ANSES Ligue Contre le Cancer Fondation ARC pour la Recherche sur le Cancer, ARC Ligue Contre le Cancer Agence Française de Sécurité Sanitaire de l'Environnement et du Travail, AFSSET Institut National Du Cancer, INCa Fondation de France, We would like to thank the clinical research nurses who were in charge of participants’ interview, anthropometric measurements and biological sample collection (Anne‐Laure Astolfi, Coline Bernard, Oriane Boyer, Marie‐Hélène De Campo, Sandrine Margaroli, Louise N'Diaye, Sabine Perrier‐Bonnet). We also would like to thank Christian Prad and Nadine Soller for help with patient medical data collection within the Hérault Cancer Registry (Registre des tumeurs de l'Hérault, Montpellier, France) and Cécile Gaffory and Valérie Ondet for technical assistance (CeRePP). Finally, we are grateful to the EPICAP study Group: Urologists: Drs Didier Ayuso, Bruno Ségui, Vincent Abd El Fattah (Centre Hospitalier Bassin de Thau, Sète, France), Alain Guillaume, Jean‐Paul Constans, Olivier Delbos, Pierre Lanfray, Damien Rizet, Etienne Cuénant (Cabinet Urologie du Polygone, Montpellier, France), Michel Locci (Centre Hospitalier, Béziers, France), Etienne Cuénant (Clinique Ste Thérèse, Sète, France), Nicolas Drianno, Bernard Marc, Paulo Soares (Polyclinique Saint Privat, Béziers, France), Antoine Faix, Samer Abdel Hamid, Bruno Ségui (Service urologie, Clinique Beau Soleil, Montpellier, France), Samer Abdel Hamid (Clinique Saint Louis, Ganges, France), Thibaut Murez, Grégoire Poinas, Laurent Cabaniols, Maxime Robert, Rodolphe Thuret (Centre Hospitalo‐Universitaire, Hôpital Lapeyronie, Montpellier, France). Pathologists: Drs Didier Brel, Lysiane Schweizer, Philippe Nayraud, C. Lecam‐Savin (Inopath‐Biomed 34), Roland Daniel, Jean Baptiste Perdigou, Chantal Compan, Mireille Granier, Agnès Grranier, Ruth Borges‐Reis, Alena Badsi, Jean Louis Bouzigues, Elisabeth Broquerie (Inopath‐Labosud) Joëlle Simony, Frédéric Bibeau, Pierre Baldet, Isabelle Serre, Valérie Costes (Centre Hospitalo‐Universitaire, Hôpital Lapeyronie, Montpellier), Marie Laure Gaume (Sète). Biologists: Drs F. Montels (Service de Biologie Médicale, Institut du Cancer de Montpellier, Montpellier, France) and Labosud laboratories: Drs François et Pascal Dumas (Béziers, France), Martine Buono (Sète, France), Isabelle Bonnefille (Lodeve, France), Georges Ruiz (Lunel, France), Didier Paleirac (Clermont‐l'Hérault, France). The EPICAP‐chrono project was funded by Institut National du Cancer, Fondation ARC and Ligue nationale contre le cancer. The EPICAP study was funded by Ligue nationale contre le cancer, Ligue contre le cancer du Val de Marne, Fondation de France, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES). The first author has been granted by a Paris‐Sud University doctoral allowance., Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset-Université Paris Cité (UPCité)

المصدر: International Journal of Cancer
International Journal of Cancer, Wiley, 2020, 147 (11), pp.3119-3129. ⟨10.1002/ijc.33139⟩
International Journal of Cancer, 2020, 147 (11), pp.3119-3129. ⟨10.1002/ijc.33139⟩

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Genotyping Techniques, Population, interaction, Nerve Tissue Proteins, [SDV.CAN]Life Sciences [q-bio]/Cancer, night work, Polymorphism, Single Nucleotide, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Circadian Clocks, Internal medicine, Basic Helix-Loop-Helix Transcription Factors, medicine, Humans, SNP, Genetic Predisposition to Disease, Circadian rhythm, education, Aged, education.field_of_study, NPAS2, business.industry, ARNTL Transcription Factors, Prostatic Neoplasms, Shift Work Schedule, Cancer, Nuclear Receptor Subfamily 1, Group F, Member 1, Odds ratio, Middle Aged, medicine.disease, prostate cancer, 3. Good health, pathway analysis, ARNTL, Logistic Models, Case-Control Studies, 030220 oncology & carcinogenesis, Neoplasm Grading, business, polymorphisms, circadian genes

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c81f9eba757ad1584de9ec655768118dTest
https://hal.archives-ouvertes.fr/hal-03109203Test

المؤلفون: Christèle Desbois-Mouthon, Aziz Zaanan, Claire Calmel, Christophe Louvet, Françoise Praz, Hélène Blons, Julien Taieb, Brice Gayet, Pierre Validire, Yann Parc, Yves Le Bouc, Julie Henriques, Claire Goumard, Magali Svrcek, Fatiha Merabtene, Jean-François Fléjou

المساهمون: Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de chirurgie digestive, générale et cancérologique [CHU HEGP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service de Pathologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de biologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Unité Mixte de Service d'Imagerie et de Cytométrie [CHU Saint-Antoine] (UMS LUMIC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de chirurgie générale et digestive [CHU Saint-Antoine], Institut Mutualiste de Montsouris (IMM), Service de gastroenterologie [CHU HEGP], Centre National de la Recherche Scientifique (CNRS)

المصدر: Cellular Oncology
Cellular Oncology, IOS Press, 2020, 43 (2), pp.237-247. ⟨10.1007/s13402-019-00484-6⟩

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Multivariate analysis, Colorectal cancer, Kaplan-Meier Estimate, Gastroenterology, Receptor, IGF Type 1, 0302 clinical medicine, IGF1R, Stage (cooking), Receptor, Aged, 80 and over, Reverse Transcriptase Polymerase Chain Reaction, General Medicine, Middle Aged, Immunohistochemistry, 3. Good health, Colon cancer, Gene Expression Regulation, Neoplastic, Oncology, 030220 oncology & carcinogenesis, Colonic Neoplasms, Molecular Medicine, Female, Adult, medicine.medical_specialty, IGF-II/IGF2, Disease-free survival, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, Humans, RNA, Messenger, MSI, Insulin-like growth factor 1 receptor, Aged, Neoplasm Staging, Retrospective Studies, Proportional hazards model, business.industry, Retrospective cohort study, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, KRAS/BRAF, body regions, 030104 developmental biology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b874b9fe176b58db90ec0457f2a0461bTest
https://hal.sorbonne-universite.fr/hal-02877818/documentTest

المؤلفون: Karen Stein, Chiun Hsu, Michael J. Pishvaian, Armando Santoro, Kenji Tamura, Kyaw L. Aung, Janice M. Mehnert, Antoine Hollebecque, Emily K. Bergsland, Patrick A. Ott, Sarina Anne Piha-Paul, Elena Elez, Christophe Le Tourneau, Roger B. Cohen, Jan H.M. Schellens, Igor Puzanov, Toshihiko Doi, M. Gould, Bert H. O'Neil, Ping Yang

المساهمون: Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Merck Sharp and Dohme, MSD Meso Scale Diagnostics, MSD MedImmune AstraZeneca AbbVie North Carolina GlaxoSmithKline Foundation Meso Scale Diagnostics, MSD Merck Sharp and Dohme, MSD Roche, Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). Study management support was provided by Pradeep Thanigaimani, BS, of MSD, and additional statistical support was provided by Chao Gao, PhD, formerly of MSD and funded by MSD. Additional study support was provided by Melanie Leiby, PhD, of MSD, and Jennifer Smedberg, an employee of ExecuPharm on assignment to Merck. Medical writing and editorial assistance was provided by Sheri Arndt, PharmD, of C4 MedSolutions LLC (Yardley, PA), a CHC Group company. This assistance was funded by MSD., Janice M. Mehnert has acted as a paid advisor or consultant for and/or received grants from Merck for work performed as part of the current study and from Merck, Pfizer, EMD Serono, Boehringer Ingelheim, Amgen, AstraZeneca, Bristol‐Myers Squibb, Incyte, and MacroGenics for work performed outside of the current study. Emily Bergsland has received grants to her institution from Merck and Novartis for work performed outside of the current study. Bert H. O’Neil is a full‐time employee of Eli Lilly. Armando Santoro has acted as a member of the Speakers' Bureau for Takeda, Bristol‐Myers Squibb, Roche, AbbVie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, ArQule, Eli Lilly, Sandoz, Eisai, Novartis, Bayer, and MSD, as a member of the advisory board for Bristol‐Myers Squibb, Servier, Gilead, Pfizer, Eisai, Bayer, and MSD, and as a paid consultant for ArQule and Sanofi for work performed outside of the current study. Jan H. M. Schellens has received personal fees from and is a patent holder for Modra Pharmaceuticals for oral taxanes and has acted as a paid consultant for Diopharm. Roger B. Cohen has received a grant to his institution from Merck for work performed as part of the current study. Toshihiko Doi has acted as a paid consultant for and received grants from Eli Lilly, Chugai Pharma, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Amgen, Taiho, Novartis, Merck Serono, Janssen, Boehringer Ingelheim, Takeda, Pfizer, Sumitomo Dainippon, Bristol‐Myers Squibb, AbbVie, Bayer, Eisai, Rakuten Medical, and Quintiles for work performed outside of the current study. Patrick A. Ott has received grants and/or personal fees from Bristol‐Myers Squibb, Genentech, Celldex, CytomX, Pfizer, Alexion, Amgen, Novartis, Neon Therapeutics, ARMO BioSciences, AstraZeneca, and Array for work performed outside of the current study. Michael J. Pishvaian has received grants to his institution from Merck, AstraZeneca/MedImmune, Halozyme, Bavarian Nordic, AbbVie, Celldex, Pfizer, Novartis, Boston Biomedical, Tesaro, Bristol‐Myers Squibb, Celgene, Genentech, ARMO BioSciences, Bayer, Calithera, Curegenix, FibroGen, Gilead, GlaxoSmithKline, Karyopharm, Regeneron, and Pharmacyclics and personal fees and/or nonfinancial support as a paid consultant, advisor, or member of the Speaker's Bureau from Merck, AstraZeneca/MedImmune, Halozyme, Sirtex Medical, Caris Life Sciences, Rafael Pharmaceuticals, Ipsen/Merrimack, RenovoRx, Perthera, and Celgene for work performed outside of the current study. Igor Puzanov has acted as a paid consultant for Amgen for work performed outside of the current study. Chiun Hsu has received grants from AstraZeneca, Bristol‐Myers Squibb/ONO, Eli Lilly, Merck Serono, MSD, Novartis, and Roche for work performed outside of the current study. Christophe Le Tourneau has received grants from MSD for work performed as part of the current study and personal fees and/or nonfinancial support from Bristol‐Myers Squibb, Merck Serono, MSD, Roche, AstraZeneca, GlaxoSmithKline, Rakuten, and Nanobiotix for work performed outside of the current study. Antoine Hollebecque has received personal fees and/or nonfinancial support from Amgen, Gritstone Oncology, Merck Serono, Eli Lilly, Eisai, and Servier for work performed outside of the current study. Elena Élez has received grants, personal fees, and/or nonfinancial support from Amgen, Sanofi, Merck Serono, Pierre Fabre, Roche, and Servier for work performed outside of the current study. Marlena Gould works as a contractor for MSD. Ping Yang is an employee of MSD, China. Karen Stein is an employee of MSD. Sarina A. Piha‐Paul has received research support from MSD for work performed as part of the current study and research support from the National Institutes of Health/National Cancer Institute, GlaxoSmithKline, AbbVie, Aminex Therapeutics, BioMarin Pharmaceutical Inc, Boehringer Ingelheim, Bristol‐Myers Squibb, Cerulean Pharma, Chugai Pharma, XuanZhu Biophama, Incyte, Jacobio, Principia Biopharma, Pieris Pharmaceuticals, Novartis, Five Prime Therapeutics, Genmab, Pfizer, Puma Biotechnology, Helix BioPharma, Curis, NewLink Genetics/Blue Link, MedImmune, Medivation, Merck Sharp and Dohme Corporation, Rapt Therapeutics, Seattle Genetics, Taiho, TransThera Biosciences, and Tesaro for work performed outside of the current study. The other authors made no disclosures.

المصدر: Cancer
Cancer, Wiley, 2020, 126 (13), pp.3021-3030. ⟨10.1002/cncr.32883⟩

مصطلحات موضوعية: Male, Cancer Research, [SDV]Life Sciences [q-bio], Programmed Cell Death 1 Receptor, Pembrolizumab, Neuroendocrine tumors, Gastroenterology, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Clinical endpoint, 030212 general & internal medicine, KEYNOTE-028, Fatigue, Aged, 80 and over, Alanine Transaminase, Middle Aged, 3. Good health, Diarrhea, Neuroendocrine Tumors, Oncology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Cohort, Disease Progression, Female, immunotherapy, pembrolizumab, medicine.symptom, Adult, medicine.medical_specialty, Carcinoid tumors, Carcinoid Tumor, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, 03 medical and health sciences, Hypothyroidism, Internal medicine, medicine, Humans, carcinoid tumors, programmed death–ligand 1, antitumor activity, Aspartate Aminotransferases, Adverse effect, Aged, pancreatic neuroendocrine tumors, business.industry, medicine.disease, Pancreatic Neoplasms, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::596af85972f505b3a787fdec0d6eac09Test
https://hal.archives-ouvertes.fr/hal-02927423Test

المؤلفون: Julien Fraisse, Carine Bellera, D. Tosi, D. Dinart, Caroline Mollevi

المساهمون: Institut du Cancer de Montpellier (ICM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), The presented research was supported by a grant of the French National Cancer Institute (INCA-Grant n°SHS-ESP 2015–164)., Malbec, Odile

المصدر: BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.60. ⟨10.1186/s12885-021-07782-z⟩
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Phases of clinical research, Targeted therapy, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Tumor Cells, Cultured, Cancer, Aged, 80 and over, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Combined Modality Therapy, 3. Good health, Gene Expression Regulation, Neoplastic, Survival Rate, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Lymphatic Metastasis, Toxicity, Female, Research Article, Adult, medicine.medical_specialty, Context (language use), Dose finding study, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Genetics, medicine, Biomarkers, Tumor, Humans, Neoplasm Invasiveness, Aged, Retrospective Studies, Optimal biological dose, business.industry, Immunotherapy, Phase 1 clinical trial, medicine.disease, Clinical trial, 030104 developmental biology, Biological target, Case-Control Studies, Neoplasm Recurrence, Local, business, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0373660f26c1a80bda1adfb736f266a5Test
https://www.hal.inserm.fr/inserm-03217931Test

المؤلفون: Marion Sassier, Matthieu Resche-Rigon, Céleste Lebbé, Pirayeh Eftekhari, Franck Rouby, C. Pages, Jean-François Gautier, Philippe Boudou, Nicole Basset-Seguin, Samia Mourah, Martine Bagot, Laetitia Da Meda, Sylvine Pinel, Marie-Léa Gauci, Barouyr Baroudjian, Tiphaine Vidal-Trecan, Isabelle Madelaine-Chambrin

المساهمون: Institut de Neurosciences des Systèmes (INS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)

المصدر: Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, Springer Verlag, 2018, 67 (8), pp.1197-1208. ⟨10.1007/s00262-018-2178-0⟩

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Immunology, Type 2 diabetes, Gastroenterology, 03 medical and health sciences, Insulin resistance, Internal medicine, Diabetes mellitus, medicine, Humans, Immunology and Allergy, CTLA-4 Antigen, Adverse effect, Melanoma, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, Aged, 80 and over, Type 1 diabetes, business.industry, Incidence, [SCCO.NEUR]Cognitive science/Neuroscience, Antibodies, Monoclonal, Retrospective cohort study, Immunotherapy, Middle Aged, Prognosis, medicine.disease, Diabetes Mellitus, Type 1, 030104 developmental biology, Diabetes Mellitus, Type 2, Oncology, Female, France, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee56e185298d4b608a37254e9d155019Test
https://hal.archives-ouvertes.fr/hal-03623644Test

المؤلفون: Giulia Berzero, Arnault Tauziede-Espariat, Luisa Bellu, Sophie Peeters, Marc Sanson, Pascale Varlet, Eduardo Parraga, Laurent Capelle, Natalia Shor, Alexandre Roux, Didier Dormont, J. Pallud, Catherine Oppenheim, Emmanuèle Lechapt, Edouard Dezamis, Myriam Edjlali, Frédéric Dhermain, Gilles Zah-Bi, Marc Zanello, Fabrice Chrétien

المساهمون: Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Biomarqueurs en imagerie : neuro développement et pathologies cérébrales (Ima-Brain [Paris]), Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), University of California [Los Angeles] (UCLA), University of California, Service de Neuroradiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Algorithms, models and methods for images and signals of the human brain (ARAMIS), Sorbonne Université (SU)-Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Département de radiothérapie [Gustave Roussy], Institut Gustave Roussy (IGR), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), University of California (UC), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)

المصدر: Neuro-Oncology
Neuro-Oncology, Oxford University Press (OUP), 2020, 22 (7), pp.993-1005. ⟨10.1093/neuonc/noaa022⟩
Neuro Oncol
Neuro-Oncology, 2020, 22 (7), pp.993-1005. ⟨10.1093/neuonc/noaa022⟩

مصطلحات موضوعية: Male, Cancer Research, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, 1p/19q Codeletion, Gastroenterology, Cohort Studies, 0302 clinical medicine, Medicine, Sequence Deletion, Brain Neoplasms, Homozygote, Increased Mitosis, IDH-mutant, Middle Aged, Isocitrate Dehydrogenase, 3. Good health, Velocity index, Isocitrate dehydrogenase, Oncology, Chromosomes, Human, Pair 1, 030220 oncology & carcinogenesis, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], Female, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Adult, medicine.medical_specialty, Oligodendroglioma, Clinical Investigations, Malignancy, World health, 03 medical and health sciences, Internal medicine, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Tumor growth, Grading (tumors), neoplasms, Retrospective Studies, Imaging growth rate, 1p/19q codeletion, business.industry, Editorials, [INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], medicine.disease, nervous system diseases, Mutation, Neurology (clinical), business, Chromosomes, Human, Pair 19, 030217 neurology & neurosurgery, Biomarkers

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1fe7b67cfbfd1a66a6aec2c5800109bTest
https://hal.archives-ouvertes.fr/hal-03139276Test

المؤلفون: Kaustav P. Shah, Javid Moslehi, Douglas B. Johnson, Haocan Song, Fei Ye, Justin M. Balko, Joe-Elie Salem

المساهمون: Vanderbilt University School of Medicine [Nashville], Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Gestionnaire, Hal Sorbonne Université, Service de Pharmacologie médicale [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

المصدر: Cancer Immunology Research
Cancer Immunology Research, American Association for Cancer Research, 2020, 8 (7), pp.851-855. ⟨10.1158/2326-6066.CIR-19-0986⟩
Cancer Immunology Research, 2020, 8 (7), pp.851-855. ⟨10.1158/2326-6066.CIR-19-0986⟩
Cancer Immunol Res

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Myocarditis, Adolescent, [SDV]Life Sciences [q-bio], Programmed Cell Death 1 Receptor, Immunology, Ipilimumab, Article, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Risk Factors, Internal medicine, Pharmacovigilance, medicine, Humans, Immunologic Factors, CTLA-4 Antigen, Young adult, Adverse effect, Melanoma, Aged, Pneumonitis, Aged, 80 and over, Hepatitis, business.industry, Age Factors, Length of Stay, Middle Aged, medicine.disease, 3. Good health, Hospitalization, [SDV] Life Sciences [q-bio], 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Immunotherapy, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df8051df7e975288586a2c82767394fTest
https://hal.sorbonne-universite.fr/hal-02948375Test